We have developed a new series of immunosuppressant with improved pharmacokinetic properties as the second-generation of colchicine analogs, which were designed based on the privileged structure derived from our previous work. In particular, we identified an analog (14), which exhibited a potent in vitro activity (IC50: 5nM) in MLR and excellent in vivo efficacy in the Zymosan A-induced arthritis model, in the Carrageenan-induced edema ...
[Hewlins, Stuart A.; Murphy, John A.; Lin, Jian; Hibbs, David E.; Hursthouse, Michael B. Journal of the Chemical Society - Perkin Transactions 1, 1997 , # 10 p. 1559 - 1570]
